Reports Sanofi-Aventis (SNY) On The Prowl For Mergers
Tweet
Share
E-mailGet Alerts SNY Hot Sheet
Join SI Premium – FREE
According to reports from the Financial Times, Sanofi-Aventis (NYSE: SNY) in on the prowl for acquisitions to expand and diversify its operations, in the wake of Pfizer's (NYSE: PFE) $68 billion merger with Wyeth (NYSE: WYE).
Potential takeover targets for Sanofi include long-rumored merger partner Bristol-Myers Squibb Co. (NYSE: BMY). In addition, Amgen (Nasdaq: AMGN) and Biogen Idec (Nasdaq: BIIB) could be potential targets. Crucell (Nasdaq: CRXL), the last significant independent vaccine maker, could also be a target for Sanofi.
An analyst at UBS estimates Sanofi-Aventis could raise $22-$26 billion for deals.
Potential takeover targets for Sanofi include long-rumored merger partner Bristol-Myers Squibb Co. (NYSE: BMY). In addition, Amgen (Nasdaq: AMGN) and Biogen Idec (Nasdaq: BIIB) could be potential targets. Crucell (Nasdaq: CRXL), the last significant independent vaccine maker, could also be a target for Sanofi.
An analyst at UBS estimates Sanofi-Aventis could raise $22-$26 billion for deals.
You May Also Be Interested In
- enVVeno Medical (NVNO) files $100M mixed shelf
- SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
- Andersen closes secondary offering of 4.9M shares at $44 each
Create E-mail Alert Related Categories
Insiders' Blog, RumorsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
